Figures & data
Figure 1. Study schematic.
Figure 2. Patient selection.
Table 1. Baseline patient characteristics for unweighted and weighted study population.
Figure 3. Standardized differences in baseline characteristics for carfilzomib vs pomalidomide for the unweighted and weighted study population.
Table 2. Healthcare resource utilization and costs for the unweighted and weighted study population.
Figure 4. Mean monthly costs by quarter since initiation of therapy for weighted study population. (A) Total healthcare costs. (B) Multiple myeloma-related healthcare costs by quarter since initiation of therapy.
